Prevalence and Impact of Minority Variant Drug Resistance Mutations in Primary HIV-1 Infection
Open Access
- 16 December 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12), e28952
- https://doi.org/10.1371/journal.pone.0028952
Abstract
To evaluate minority variant drug resistance mutations detected by the oligonucleotide ligation assay (OLA) but not consensus sequencing among subjects with primary HIV-1 infection.Observational, longitudinal cohort study. Consensus sequencing and OLA were performed on the first available specimens from 99 subjects enrolled after 1996. Survival analyses, adjusted for HIV-1 RNA levels at the start of antiretroviral (ARV) therapy, evaluated the time to virologic suppression (HIV-1 RNA<50 copies/mL) among subjects with minority variants conferring intermediate or high-level resistance.Consensus sequencing and OLA detected resistance mutations in 5% and 27% of subjects, respectively, in specimens obtained a median of 30 days after infection. Median time to virologic suppression was 110 (IQR 62-147) days for 63 treated subjects without detectable mutations, 84 (IQR 56-109) days for ten subjects with minority variant mutations treated with ≥3 active ARVs, and 104 (IQR 60-162) days for nine subjects with minority variant mutations treated with <3 active ARVs (p = .9). Compared to subjects without mutations, time to virologic suppression was similar for subjects with minority variant mutations treated with ≥3 active ARVs (aHR 1.2, 95% CI 0.6-2.4, p = .6) and subjects with minority variant mutations treated with <3 active ARVs (aHR 1.0, 95% CI 0.4-2.4, p = .9). Two subjects with drug resistance and two subjects without detectable resistance experienced virologic failure.Consensus sequencing significantly underestimated the prevalence of drug resistance mutations in ARV-naïve subjects with primary HIV-1 infection. Minority variants were not associated with impaired ARV response, possibly due to the small sample size. It is also possible that, with highly-potent ARVs, minority variant mutations may be relevant only at certain critical codonsKeywords
This publication has 55 references indexed in Scilit:
- Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation ClassesThe Journal of Infectious Diseases, 2011
- Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment FailureJAMA, 2011
- Nucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance MutationPLOS ONE, 2010
- Nevirapine Resistance by Timing of HIV Type 1 Infection in Infants Treated with Single‐Dose NevirapineClinical Infectious Diseases, 2010
- Association between Detection of HIV‐1 DNA Resistance Mutations by a Sensitive Assay at Initiation of Antiretroviral Therapy and Virologic FailureClinical Infectious Diseases, 2010
- Pre‐existing Minority Drug‐Resistant HIV‐1 Variants, Adherence, and Risk of Antiretroviral Treatment FailureThe Journal of Infectious Diseases, 2010
- Low Frequency Nonnucleoside Reverse‐Transcriptase Inhibitor–Resistant Variants Contribute to Failure of Efavirenz‐Containing Regimens in Treatment‐Experienced PatientsThe Journal of Infectious Diseases, 2010
- Optimization of the Oligonucleotide Ligation Assay, a Rapid and Inexpensive Test for Detection of HIV-1 Drug Resistance Mutations, for Non-North American VariantsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment EfficacyPLoS Medicine, 2008
- Simple PCR Assays Improve the Sensitivity of HIV-1 Subtype B Drug Resistance Testing and Allow Linking of Resistance MutationsPLOS ONE, 2007